Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 and CYP2E1 Gene Polymorphisms and Their Influence on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.

Asian Pacific journal of cancer prevention : APJCP - 1 Oct 2025

Gudur Rashmi A, Gudur Anand K, Bhosale Suresh J, Datkhile Kailas D

Abstract excerpt

BACKGROUND: The majority of breast cancer cases are treated with invasive chemotherapy, which typically involves combinations of drugs as part of the standard therapeutic regimen. However, responses to chemotherapeutic agents and treatment outcomes can vary significantly among patients, and the occurrence of acute toxicity remains unpredictable. Phase I drug detoxification genes, such as those encoding cytochrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2E1

Share to Doxorubicin

Share to Follow-Up Studies

Share to Paclitaxel

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41148602
DOI: 10.31557/APJCP.2025.26.10.3629
PMCID: PMC12894792

Genes

CYP2E1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 and CYP2E1 Gene Polymorphisms and Their Influence on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.PMID 41148602Read ↗

The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.Semantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and EfficacySemantic proximity Read ↗

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read ↗

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.Semantic proximity Read ↗

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patientsSemantic proximity Read ↗

Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen TherapySemantic proximity Read ↗

Toxicity and Pharmacogenomic Biomarkers in Breast Cancer ChemotherapySemantic proximity Read ↗

Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.Semantic proximity Read ↗

Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.